Brokerages Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Price Target at $66.67

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $66.6667.

Several research firms have commented on RVPH. Wall Street Zen raised shares of Reviva Pharmaceuticals to a “sell” rating in a research report on Saturday. D. Boral Capital cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, March 5th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Thursday, January 22nd. Chardan Capital reaffirmed a “buy” rating and issued a $40.00 price target on shares of Reviva Pharmaceuticals in a report on Monday, January 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $80.00 price objective on shares of Reviva Pharmaceuticals in a report on Tuesday, December 23rd.

Reviva Pharmaceuticals Trading Down 6.8%

RVPH opened at $2.47 on Thursday. The firm has a market cap of $14.42 million, a price-to-earnings ratio of -0.27 and a beta of 0.10. Reviva Pharmaceuticals has a 12 month low of $2.37 and a 12 month high of $23.40. The stock has a fifty day moving average price of $5.40 and a 200-day moving average price of $8.47.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RVPH. Armistice Capital LLC acquired a new stake in Reviva Pharmaceuticals in the second quarter worth about $1,026,000. 683 Capital Management LLC acquired a new position in shares of Reviva Pharmaceuticals during the second quarter valued at about $381,000. Geode Capital Management LLC increased its holdings in shares of Reviva Pharmaceuticals by 87.6% during the fourth quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock valued at $293,000 after acquiring an additional 489,711 shares in the last quarter. Persistent Asset Partners Ltd raised its position in shares of Reviva Pharmaceuticals by 300.0% in the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after purchasing an additional 480,864 shares during the last quarter. Finally, State Street Corp raised its position in shares of Reviva Pharmaceuticals by 202.4% in the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after purchasing an additional 256,500 shares during the last quarter. 63.18% of the stock is currently owned by hedge funds and other institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.